Jeffery W. Strovel, Ph.D.
Senior Vice President, Translational Research
Dr. Strovel has significant experience in developing and implementing innovative platforms for the discovery and development of biomarkers. For several years prior to the beginning of Noble, he was the Head of Discovery Research at Avalon Pharmaceuticals where he played a critical role in the development of many of the company’s novel biomarker-driven discovery systems while simultaneously leading discovery efforts including the company’s seminal product development candidate, a mechanistically novel cancer drug candidate targeting a major, previously intractable, target pathway in colorectal cancer. For this and other achievements, Dr. Strovel was recognized in four different years with the company’s “invention of the year” award. In addition, Dr. Strovel critically evaluated licensing opportunities, directed a team responsible for the discovery and validation of biomarkers in clinical specimens, and managed the biomarker assay group responsible for the development of pre-clinical and clinical biomarkers and the acquisition, processing, and interpretation of clinical biomarker data. Dr. Strovel has also led programs for small molecule drug discovery and development including drug target discovery, Hit to Lead, Drug lead optimization, in vitro and pharmacodynamic biomarker discovery. Earlier in his career, Dr. Strovel held positions at the University of Maryland and the National Cancer Institute.